XOMA News and Press, XOMA Corporation From 09/07/22

EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will p...

XOMA press release ( NASDAQ: XOMA ): Q2 GAAP EPS of -$0.53 misses by $0.37 . Revenue of $0.98M (+8.9% Y/Y) misses by $3.29M . The Company ended December 31, 2021, with cash and restricted cash of $95.4 million. After paying its remaining debt obligations in...

The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rezolute and Day One led both companies to announce plans to move their assets into Phase ...

These July sample selections are the current top positive/negative forensic stocks out of 8,000 stocks based on combined scores from four top forensic algorithms. The January Positive Forensic portfolio is beating the S&P 500 by +1.59% YTD. The Negative portfolio is beating by +13...

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules •  $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” ...

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will pre...

While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but something special is hidden underneath. Those looking to get in before the story plays o...

XOMA press release (NASDAQ:XOMA): Q1 GAAP EPS of -$0.32 beats by $0.21. Revenue of $3.11M (+718.4% Y/Y) misses by $0.06M. Ended the first quarter of 2022 with cash and restricted cash of $88.6 million and no debt on XOMA’s balance sheet. For further details see: XOMA GAAP EPS of ...

Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022.  Rezolute has announced its intention to move RZ358 into Phase 3 clinical development. Roche’s ...

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will p...